Literature DB >> 28275334

Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein.

Stella Maris Mattaloni1, Carine Arnoni2, Rosario Céspedes3, Claudia Nonaka4, Carolina Trucco Boggione1, Melina Eliana Luján Brajovich1, Andrea Trejo3, Néstor Zani4, Claudia Silvia Biondi5, Lilian Castilho6, Carlos Miquel Cotorruelo1.   

Abstract

BACKGROUND: Kell null (K0) individuals can produce anti-Ku, an antibody against many epitopes in the Kell glycoprotein, after transfusion and/or pregnancy. Since sensitized K0 patients are rare, little is known about anti-Ku clinical relevance and in particular about its association to hemolytic disease of the fetus and newborn. CASE REPORT: This work describes a case of neonatal hyperbilirubinemia due to immune-mediated erythrocyte destruction by an alloantibody directed against the Kell glycoprotein. Serologic and molecular approaches identified an anti-Ku alloantibody in maternal serum. A homozygous IVS3 + 1g>a point mutation (KEL*02N.06 allele) was found to be responsible for the lack of Kell antigen expression in the mother's red blood cell and subsequent alloimmunization after a previous pregnancy. Even though in most cases Kell antibodies are clinically severe and may cause suppression of erythropoiesis, in our case the newborn had a moderate anemia and hyperbilirubinemia that was successfully treated with phototherapy without requiring exchange transfusion. Serological and molecular studies performed in the proband's family members allowed us to provide them with proper counseling regarding alloimmunization after transfusion and/or pregnancy.
CONCLUSIONS: This case enlarges the understanding of the clinical significance of alloantibodies against Kell blood group antigens.

Entities:  

Keywords:  Alloimmunization; Anti-Ku alloantibody; Hemolytic disease of the fetus and newborn; K0 phenotype; Kell blood group system; Kell null phenotype

Year:  2016        PMID: 28275334      PMCID: PMC5318919          DOI: 10.1159/000448381

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  18 in total

Review 1.  The Kell blood group system: Kell and XK membrane proteins.

Authors:  S Lee; D Russo; C M Redman
Journal:  Semin Hematol       Date:  2000-04       Impact factor: 3.851

2.  Molecular defects underlying the Kell null phenotype.

Authors:  S Lee; D C Russo; A P Reiner; J H Lee; M Y Sy; M J Telen; W J Judd; P Simon; M J Rodrigues; T Chabert; J Poole; S Jovanovic-Srzentic; C Levene; V Yahalom; C M Redman
Journal:  J Biol Chem       Date:  2001-05-24       Impact factor: 5.157

Review 3.  Kell and Kx blood group systems.

Authors:  Gregory A Denomme
Journal:  Immunohematology       Date:  2015

4.  Genetic basis of the K(0) phenotype in the Swedish population.

Authors:  Elisabet S Wester; Jill R Storry; Karin Schneider; Birgitta Nilsson Sojka; Joyce Poole; Martin L Olsson
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

5.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

Authors:  Pierre Bruhns; Bruno Iannascoli; Patrick England; David A Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron
Journal:  Blood       Date:  2008-11-18       Impact factor: 22.113

6.  Three novel alleles in the Kell blood group system resulting in the Knull phenotype and the first in a Native American.

Authors:  Joann M Moulds; Rosemary Persa; Darbi Rierson; Katrina L Billingsley; Ghislain T Noumsi; Kim Hue-Roye; Marion E Reid
Journal:  Transfusion       Date:  2013-04-15       Impact factor: 3.157

7.  Molecular basis of the Kell-null phenotype: a mutation at the splice site of human KEL gene abolishes the expression of Kell blood group antigens.

Authors:  L C Yu; Y C Twu; C Y Chang; M Lin
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

8.  Molecular Basis of KELnull Phenotype in Brazilians.

Authors:  Edmir Boturão-Neto; Mihoko Yamamoto; Akemi Kuroda Chiba; Elisa Yuriko Sugano Kimura; Maria do Carmo Valgueiro Costa de Oliveira; Cláudia Lumack do Monte Barretto; Mércia Maria Alves Nunes; Sérgio Roberto Lopes Albuquerque; Marcos Daniel de Deus Santos; José Orlando Bordin
Journal:  Transfus Med Hemother       Date:  2014-12-19       Impact factor: 3.747

9.  Use of recombinant erythropoietin for the management of severe hemolytic disease of the newborn of a K0 phenotype mother.

Authors:  Antonia Manoura; Eftychia Korakaki; Eleftheria Hatzidaki; Emmanuel Saitakis; Sofia Maraka; Isabella Papamastoraki; Emmanuel Matalliotakis; Kaliopi Foundouli; Christine Giannakopoulou
Journal:  Pediatr Hematol Oncol       Date:  2007 Jan-Feb       Impact factor: 1.969

10.  [The Ko phenotype and fetal-maternal allo-immunization].

Authors:  A Fourmaintraux; D Vitrac; J B Mariette; F Brunel
Journal:  Arch Fr Pediatr       Date:  1993-11
View more
  1 in total

1.  Generation of 'designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 gene-edited human-induced pluripotent stem cells.

Authors:  Priyanka Pandey; Nanyan Zhang; Brian R Curtis; Peter J Newman; Gregory A Denomme
Journal:  J Cell Mol Med       Date:  2021-09-21       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.